SPARK Therapeutics pulls off a $161M IPO

jeffrey-d-marrazzoSpark Therapeutics, the Philadelphia firm specializing in gene therapy treatments who just last week announced the start of the United States first clinical trial to treat Choroideremia using it’s gene therapy product SPK-CHM, has gone public today on the NASDAQ bringing in $161 million during it’s Initial Public Offering.  Chief Executive Officer Jeffrey D. Marrazzo and the team at Spark have worked closely with University of Pennsylvania and Dr. Jean Bennett to help bring the SPK-CHM Gene Therapy into phase 1 clinical trials.

Read the Philadelphia Business Journal Blog about this IPO by clicking here

Read more about this IPO on Fierce Biotech by clicking here.

News and Updates

Sign up to keep updated on the latest news, events, and research.

Tell Your Friends About Choroideremia

The Choroideremia Research Foundation Inc. is an international, non-profit organization dedicated to raising funds to find a treatment or cure for Choroideremia, a rare inherited retinal degenerative disease that causes blindness.

Copyright © 2017 The Choroideremia Research Foundation Inc.

The Choroideremia Research Foundation takes seriously our responsibility to maintain your privacy in all matters related to the Foundation. Specifically, we do not sell, rent or otherwise distribute to any individual or organization names, addresses or other information we receive through our newsletter, our website or other forms of digital or written communication.